Antonio Nunzio D’Angelo, M.Sc; Andrea Cazzulani B.Sc | Medicud Srl
Competition Sponsor: EIT Health of the European Union
Awardee Year: 2022
Medicud has developed an innovative incisional Negative Pressure Wound Therapy device to reduce infection risk. The device is mechanically powered and ultraportable, engineered to be cost effective and reduce ecological footprint thanks to the use of novel biopolymers. Surgical site infections are a global burden with on extremely high associated cost, more than 30 billions dollars are spent each year to treat infected surgical wounds. Incisional NPWT has a proven prophylactic efficacy, supported by ten years of use, unfortunately current device are highly expensive, unhandy and being battery powered and single use they have an important ecologic cost, nothing is recycled.
Medicud wants to make this treatment the gold standard prophylactic treatment for surgical incisions with its innovative solution. As of today more than 250 million major surgeries can benefit from Medicud device, making a 12 billion dollars potential market, market will be driven in the next years by increase of global population, comorbidities (diabetes, obesity…) an increased global access to surgical procedures.
To learn more about this proposal, email healthylongevity@nas.edu.